PhillyTablet Inquirer Daily News
philly.com
email
font size
options
 
Monday, October 27, 2008

Princeton-based HealthCare Ventures and several partners have invested $28 million in InfaCare, a Trevose firm that's overseeing clinical testing for its product, Stanate, which promises to help fight jaundice in newborns. Release here.

The deal shows the continued appeal of the Philadelphia area to biotech firms, and the firms' appeal to investors, but it also shows the often limited public benefits of such deals: InfaCare employs just 7 people and doesn't manufacture its own treatments. It may grow larger, or it may get picked up by a Big Pharma company as its product gets closer to market, says chief financial officer Ron Goldfuss.

InfaCare was spun off by Dr. Robert A. Vukovich's Neptune, NJ-based Wellspring Pharmaceuticals four years ago.  The company was first headquartered in Plymouth Meeting, and moved to Trevose last year, Goldfuss said.

Besides HealthCare ventures, investors backing the deal include Longitude Capital and previous investors FirstMark Capital and Atlas Ventuer, among others. Health Care Ventures partner PHarold Werner and Longitude partner Patrick Enright join the HealthCare Ventures board.



Posted by Joseph N. DiStefano @ 11:50 AM  Permalink | Post a comment
Comments   


0 comments
About Joseph N. DiStefano
Joseph N. DiStefano writes this blog to feed his PhillyDeals column in the Philadelphia Inquirer. Joe has been a member of Bloomberg LP’s New York Finance Team, wrote the book “Comcasted,” taught writing at St. Joseph’s University, and studied economics and history at Penn. Reach Joe at 215-854-5194 and JoeD@phillynews.com